Symbol | Exchange | Currency |
|---|
KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injectionInitial data from this efficacy cohort of the PEARL-1 study is anticipated in...
AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN PatientsTreatment with AL001 Slowed Clinical Progression by 47% Based on the CDR® plus NACC FTLD-SB Scale...
Lifetime real earnings of the median male worker declined by 10% from those who entered the US labor market in 1967 to those in 1983, or roughly a loss of $136,000.
Regulus Therapeutics Inc (NASDAQ: RGLS) has announced an incremental update from the first cohort of patients from its ongoing Phase 1b trial evaluating RGLS4326 in Autosomal...
The unemployment rate inched up to 6.1%, and the number of new non-farm jobs (a relatively volatile number subject to extensive revisions) came in at 266K.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Sell | Neutral | Buy | Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Buy | Buy |
| Summary | Strong Sell | Strong Sell | Sell | Strong Buy | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 801.40 | 819.87 | 801.40 | -14.00 | -1.72% | 41.88K | London | |||
| 290.60 | 291.00 | 288.20 | +3.90 | +1.36% | 488.30K | London | |||
| 197.00 | 202.00 | 197.00 | -4.50 | -2.23% | 113.95K | London | |||
| 47.13 | 47.26 | 46.56 | +0.28 | +0.60% | 15.78M | London | |||
| 874.90 | 876.00 | 868.42 | +6.90 | +0.79% | 129.84K | London | |||
| 686.50 | 710.00 | 662.00 | -12.00 | -1.72% | 350.42K | London | |||
| 1,422.50 | 1,430.50 | 1,407.00 | +8.00 | +0.57% | 276.29K | London | |||
| 103.41 | 103.78 | 103.14 | +0.81 | +0.79% | 203.71K | London | |||
| 369.40 | 374.00 | 363.20 | -2.20 | -0.59% | 140.36K | London | |||
| 5,688.30 | 5,708.00 | 5,616.00 | +69.0 | +1.23% | 269.71K | London | |||
| 173.59 | 175.60 | 173.15 | -1.35 | -0.77% | 2.42M | London | |||
| 21.59 | 21.95 | 19.25 | +2.99 | +16.08% | 6.33M | London | |||
| 8,289.00 | 8,357.00 | 8,285.00 | -8.0 | -0.10% | 379.32K | London | |||
| 450.00 | 450.00 | 450.00 | +30.00 | +7.32% | 6.21K | London | |||
| 1,331.77 | 1,339.64 | 1,329.75 | +22.27 | +1.70% | 691.76K | London |
Cohort plc, through its subsidiaries, provides various products and services in defense and security markets in the United Kingdom, Portugal, North and South America, and other European countries. The company offers electro-optical and electro-mechanical systems, such as command, control, communications, computers, intelligence, surveillance, target acquisition, and reconnaissance, as well as combat systems; communications systems; integrated command, control, and communications systems for warships and submarines; tactical radio, vehicle intercoms, field communications, and networking software and equipment; and electronic warfare operational support, managed, secure communications, cyber security, and training support services. It also provides electronic and surveillance technology services; and other defense, non-defense, and security products. In addition, the company offers training and simulation; digital forensics; and research, advice, and support services. It provides products and services for customers in the defense and security markets for land, maritime, and air applications, as well as civil markets covering the security, transport, and the oil and gas industry. Cohort plc was incorporated in 2006 and is headquartered in Reading, the United Kingdom.